Evidence map›Paper›PMID 40809063›Full record

ArticleInternational journal of pharmaceutics: X2025

Glucose-functionalized redox-responsive dihydroartemisinin prodrug nanosystem for targeted malaria therapy.

Rongrong Wang, Jiaqi Yang, Jihong Qiang, Qingxia Li, Geng Wang, Canqi Ping, Kesheng Liu, Ruili Wang, Bin Zheng, Guolian Ren and 1 more

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rongrong WangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Jiaqi YangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Jihong QiangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Qingxia LiSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Geng WangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Canqi PingSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Kesheng LiuSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Ruili WangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Bin ZhengSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Guolian RenSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Shuqiu ZhangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although malaria has been effectively controlled, it still poses a threat to global health. Artemisinins are the first-line antimalarial drugs. However, their therapeutic efficacy is significantly limited by poor solubility and short biological half-life. To overcome these limitations and enhance drug accumulation in

Indexed as

DihydroartemisininGlucose-targeted drug deliveryMalariaRedox-responsive prodrug nanoparticles

Identifiers

PMID40809063
PMCPMC12344195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.